Clinical trial NCT06897917: Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Official title: Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Opioid-Induced Constipation
Pain Cancer
Keywords: opioid-induced constipation
severe cancer pain
Oxycodone/naloxone sustained-release tablets
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2025-03-27
Enrollment: 203
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.

Detailed description: Cancer remains a significant health concern globally, with rising incidence and mortality rates. In 2022, there were 19.96 million new cancer cases and 9.74 million cancer deaths worldwide, including 4.8 million new cases and 2.6 million deaths in China. Cancer patients often experience pain during treatment, with 40% of patients reporting persistent pain, particularly moderate to severe pain, occurring in 40%-80% of cases. Unrelieved pain can exacerbate symptoms such as anxiety, depression, fatigue, insomnia, and loss of appetite, significantly impacting patients' quality of life. Opioids, represented by morphine and oxycodone, are widely used for the treatment of moderate to severe cancer pain.

Long-term opioid use often leads to gastrointestinal adverse events, with opioid-induced constipation (OIC) being the most common, significantly affecting patients' quality of life and treatment compliance. Although some guidelines recommend laxatives as prophylactic and first-line treatment for OIC, approximately half of the patients do not experience adequate symptom improvement. The mechanism of OIC primarily involves the activation of intestinal μ-opioid receptors, which is difficult to address solely with laxatives. The key to treating OIC lies in blocking the stimulation of μ-opioid receptors in the gastrointestinal tract while maintaining the analgesic effect of opioid receptors in the central nervous system.

Oxycodone/naloxone sustained-release tablets, a combination of the opioid receptor agonist oxycodone and the antagonist naloxone, effectively provide analgesia while improving OIC. Foreign studies have demonstrated that this medication significantly improves OIC while maintaining good analgesic effects, with good long-term tolerability. Mimeixin® is an oxycodone/naloxone sustained-release tablet developed with reference to the foreign-listed drug Targin®. It was approved by the National Medical Products Administration of China in June 2024 for the treatment of severe pain in adults that requires opioid analgesics for adequate control. However, clinical validation has not been conducted among Chinese cancer pain patients. Therefore, a prospective, single-arm, multicenter, real-world study is planned to evaluate the effect in bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain in real-world clinical practice.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years old, with a histological or pathological diagnosis of advanced cancer.
* Be diagnosed with severe (NRS ≥ 7 points) cancer pain, requiring regular opioid therapy.
* Diagnosed with OIC according to the Rome IV diagnostic criteria for OIC, with a BFI score ≥ 30.
* Determined by the investigator to be eligible for treatment with oxycodone/naloxone sustained-release tablets.
* Estimated survival period of more than 3 months.
* Voluntarily sign an informed consent form.

Exclusion Criteria:

* Patients with contraindications to oxycodone/naloxone sustained-release tablets (including allergy to the active ingredients or any excipients of this product; severe respiratory depression accompanied by hypoxemia and/or hypercapnia; severe chronic obstructive pulmonary disease; pulmonary heart disease; severe bronchial asthma; paralytic ileus caused by non-opioid drugs; moderate to severe liver function impairment).
* Patients with structural malformations of the gastrointestinal tract (such as intestinal obstruction, stenosis), other known gastrointestinal diseases/symptoms (including cancer metastasis to the digestive tract), or gastrointestinal digestion and absorption disorders.
* Patients with language communication barriers, cognitive impairments or mental illnesses, intracranial metastasis of tumors with consciousness disorders, or consciousness disorders caused by other reasons.
* Other situations that the investigator judges as unsuitable for inclusion in the study.

Primary outcomes:
measure: Changes of Patients' Bowel Function of day 28
timeFrame: pre-intervention, day 7, day 14, day 21 and day 28 after the intervention
Secondary outcomes:
measure: Changes of Cancer Pain with NRS
timeFrame: through study completion, an average of 4 weeks
measure: Changes of Cancer Pain with BPI-SF
timeFrame: through study completion, an average of 4 weeks
measure: Changes of breakthrough pain
timeFrame: within 24 hours
measure: Frequency of bowel movements and CSBMs
timeFrame: through study completion, an average of 4 weeks
measure: Laxative Use
timeFrame: through study completion, an average of 4 weeks
measure: Assessment of withdrawal symptoms
timeFrame: pre-intervention, day 2 and day 28 after the intervention
measure: Changes of Quality of Life with EQ-5D-5L
timeFrame: day 7, day 14, day 21 and day 28 after the intervention
measure: Changes of Quality of Life with SF-6D
timeFrame: day 7, day 14, day 21 and day 28 after the intervention
measure: Changes of Quality of Life with PAC-QOL
timeFrame: day 7, day 14, day 21 and day 28 after the intervention
measure: Incidence of adverse events (Safety Evaluation)
timeFrame: through study completion, an average of 4 weeks
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
Study officials:
affiliation: Henan Cancer Hospital
name: Suxia Luo, Doctor
role: PRINCIPAL_INVESTIGATOR
References: